Study of Stereotactic Radiosurgery With Olaparib Followed by Durvalumab and Physician's Choice Systemic Therapy in Subjects With Breast Cancer Brain Metastases

NCT04711824 · clinicaltrials.gov ↗

PHASE1,PHASE2

Phase

RECRUITING

Status

41

Enrollment

OTHER

Sponsor class

Conditions

Breast Cancer
Brain Metastases, Adult

Interventions

DRUG: Olaparib
RADIATION: Stereotactic Radiosurgery
DRUG: Durvalumab
DRUG: Physicians Choice systemic chemotherapy

Sponsor

Colette Shen

Collaborators

[object Object]
[object Object]